Advances in immunotherapy of chronic myeloid leukemia CML

Current Cancer Drug Targets

Volumn 13, Issue 7, 2013, Pages 768-774

  Held, Stefanie Andrea Erika ^a   Heine, Annkristin ^a   Mayer, Karin Tina ^a   Kapelle, Mario ^a   Georg, Dominik ^a   Wolf, Friedrich ^a   Brossart, Peter ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Chronic myeloid leukemia; Immunotherapy; Leukemia associated antigens

Indexed keywords

CD34 ANTIGEN; IPILIMUMAB; LEUKEMIA ANTIGEN; NIVOLUMAB; SURVIVIN; WT1 PROTEIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOID LEUKEMIA THERAPY; COLONY FORMING UNIT GM; DENDRITIC CELL; DISEASE ERADICATION; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LEUKEMIA RELAPSE; OVERALL SURVIVAL; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; DENDRITIC CELLS; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; TREATMENT OUTCOME;

EID: 84888037897     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096113139990086     Document Type: Article

References (63)

1. Heine, A.; Held, S. A.; Bringmann, A.; Holderried, T. A.; Brossart, P. Immunomodulatory effects of anti-angiogenic drugs. Leukemia 2011, 25, 899-905.
2. Krusch, M.; Salih, H. R. Effects of BCR-ABL inhibitors on antitumor immunity. Curr. Med. Chem. 2011, 18, 5174-5184.
3. Appel, S.; Balabanov, S.; Brummendorf, T. H.; Brossart, P. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells 2005, 23, 1082-1088.
4. Clark, R. E.; Dodi, I. A.; Hill, S. C.; Lill, J. R.; Aubert, G.; Macintyre, A. R.; Rojas, J.; Bourdon, A.; Bonner, P. L.; Wang, L.; Christmas, S. E.; Travers, P. J.; Creaser, C. S.; Rees, R. C.; Madrigal, J. A. Direct evidence that leukemic cells present HLA associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood. 2001, 98, 2887-2893.
5. Bocchia, M.; Wentworth, P. A.; Southwood, S.; Sidney, J.; McGraw, K.; Scheinberg, D. A.; and Sette, A. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995, 85, 2680-2684.
6. Ariyaratana, S.; Loeb, D. M. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert. Rev. Mol. Med. 2007, 9, 1-17.
7. Oji, Y.; Oka, Y.; Nishida, S.; Tsuboi, A.; Kawakami, M.; Shirakata, T.; Takahashi, K.; Murao, A.; Nakajima, H.; Narita, M.; Takahashi, M.; Morita, S.; Sakamoto, J.; Tanaka, T.; Kawase, I.; Hosen, N.; Sugiyama, H. WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient. Eur. J. Haematol. 2010, 85, 358-360.
8. Oka, Y.; Tsuboi, A.; Taguchi, T.; Osaki, T.; Kyo, T.; Nakajima, H.; Elisseeva, O. A.,; Oji, Y.; Kawakami, M.; Ikegame, K.; Hosen, N.; Yoshihara, S.; Wu, F.; Fujiki, F.; Murakami, M.; Masuda, T.; Nishida, S.; Shirakata, T.; Nakatsuka, S.; Sasaki, A.; Udaka, K.; Dohy, H.; Aozasa, K.; Noguchi, S.; Kawase, I.; Sugiyama, H. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 13885-13890.
9. Rezvani, K.; Yong, A. S.; Mielke, S.; Savani, B. N.; Musse, L.; Superata, J.; Jafarpour, B.; Boss, C.; and Barrett, A. J. Leukemiaassociated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008, 111, 236-242.
10. Rezvani, K.; Grube, M.; Brenchley, J. M.; Sconocchia, G.; Fujiwara, H.; Price, D. A.; Gostick, E.; Yamada, K.; Melenhorst, J.; Childs, R.; Hensel, N.; Douek, D. C.; Barrett, A. J. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003, 102, 2892-2900.
11. Rezvani, K.; Yong, A. S.; Savani, B. N.; Mielke, S.; Keyvanfar, K.; Gostick, E.; Price, D. A.; Douek, D. C.; Barrett, A. J. Graft-versusleukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007, 110, 1924-1932.
12. Gao, L.; Bellantuono, I.; Elsasser, A.; Marley, S. B.; Gordon, M. Y.; Goldman, J. M.; Stauss, H. J. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000, 95, 2198-2203.
13. Keilholz, U.; Letsch, A.; Busse, A.; Asemissen, A. M.; Bauer, S.; Blau, I. W.; Hofmann, W. K.; Uharek, L.; Thiel, E.; Scheibenbogen, C. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009, 113, 6541-6548.
14. Barrett, J.; Rezvani, K. Neutrophil granule proteins as targets of leukemia-specific immune responses. Curr. Opin. Hematol. 2006, 13, 15-20.
15. Zhang, P.; Nelson, E.; Radomska, H. S.; Iwasaki-Arai, J.; Akashi, K.; Friedman, A. D.; Tenen, D. G. Induction of granulocytic differentiation by 2 pathways. Blood 2002, 99, 4406-4412.
16. Molldrem, J.; Dermime, S.; Parker, K.; Jiang, Y. Z.; Mavroudis, D.; Hensel, N.; Fukushima, P.; Barrett, A. J. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996, 88, 2450-2457.
17. Molldrem, J. J.; Clave, E.; Jiang, Y. Z.; Mavroudis, D.; Raptis, A.; Hensel, N.; Agarwala, V.; and Barrett, A. J. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997, 90, 2529-2534.
18. Molldrem, J. J.; Lee, P. P.; Wang, C.; Champlin, R. E.; and Davis, M. M. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 1999, 59, 2675-2681.
19. Molldrem, J. J.; Lee, P. P.; Kant, S.; Wieder, E.; Jiang, W.; Lu, S.; Wang, C.; Davis, M. M. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemiaspecific T cells. J. Clin. Invest. 2003, 111, 639-647.
20. Burchert, A.; Muller, M. C.; Kostrewa, P.; Erben, P.; Bostel, T.; Liebler, S.; Hehlmann, R.; Neubauer, A.; and Hochhaus, A. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J. Clin. Oncol. 2010, 28, 1429-1435.
21. Molldrem, J. J.; Lee, P. P.; Wang, C.; Felio, K.; Kantarjian, H. M.; Champlin, R. E.; Davis, M. M. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 2000, 6, 1018-1023.
22. Rezvani, K.; Yong, A. S.; Mielke, S.; Savani, B. N.; Jafarpour, B.; Eniafe, R.; Le, R. Q.; Musse, L.; Boss, C.; Childs, R.; John, Barrett A. Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy. Cancer Immunol. Immunother. 2012, 61, 1125-1136.
23. Scanlan, M. J.; Gure, A. O.; Jungbluth, A. A.; Old, L. J.; Chen, Y. T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 2002, 188, 22-32.
24. Oehler, V. G.; Guthrie, K. A.; Cummings, C. L.; Sabo, K.; Wood, B. L.; Gooley, T.; Yang, T.; Epping, M. T.; Shou, Y.; Pogosova-Agadjanyan, E.; Ladne, P.; Stirewalt, D. L.; Abkowitz, J. L.; Radich, J. P. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 2009, 114, 3299-3308.
25. Quintarelli, C.; Dotti, G.; De, Angelis B.; Hoyos, V.; Mims, M.; Luciano, L.; Heslop, H. E.; Rooney, C. M.; Pane, F.; Savoldo, B. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia Blood 2008, 112, 1876-1885.
26. Rezvani, K.; Yong, A. S.; Tawab, A.; Jafarpour, B.; Eniafe, R.; Mielke, S.; Savani, B. N.; Keyvanfar, K.; Li, Y.; Kurlander, R.; Barrett, A. J. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 2009, 113, 2245-2255.
27. Luetkens, T.; Schafhausen, P.; Uhlich, F.; Stasche, T.; Akbulak, R.; Bartels, B. M.; Hildebrandt, Y.; Gontarewicz, A.; Kobold, S.; Meyer, S.; Gordic, M.; Bartels, K.; Lajmi, N.; Cao, Y.; Kroger, N.; Bokemeyer, C.; Brummendorf, T. H.; Atanackovic, D. Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. Leuk. Res. 2010, 34, 1647-1655.
28. Roman-Gomez, J.; Jimenez-Velasco, A.; Agirre, X.; Castillejo, J. A.; Navarro, G.; Jose-Eneriz, E. S.; Garate, L.; Cordeu, L.; Cervantes, F.; Prosper, F.; Heiniger, A.; Torres, A. Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk. Res. 2007, 31, 1521-1528.
29. Radich, J. P.; Dai, H.; Mao, M.; Oehler, V.; Schelter, J.; Druker, B.; Sawyers, C.; Shah, N.; Stock, W.; Willman, C. L.; Friend, S.; Linsley, P. S. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 2794-2799.
30. Watari, K.; Tojo, A.; Nagamura-Inoue, T.; Nagamura, F.; Takeshita, A.; Fukushima, T.; Motoji, T.; Tani, K.; Asano, S. Identification of a melanoma antigen, PRAME, as a BCR/ABLinducible gene. FEBS Lett. 2000, 466, 367-371.
31. Conte, E.; Stagno, F.; Guglielmo, P.; Scuto, A.; Consoli, C.; Messina, A. Survivin expression in chronic myeloid leukemia. Cancer Lett. 2005, 225, 105-110.
32. Badran, A.; Yoshida, A.; Wano, Y.; Imamura, S.; Kawai, Y.; Tsutani, H.; Inuzuka, M.; Ueda, T. Expression of the antiapoptotic gene survivin in chronic myeloid leukemia. Anticancer Res. 2003, 23, 589-592.
33. Westermann, J.; Kopp, J.; van, Lessen A.; Hecker, A. C.; Baskaynak, G.; Le, Coutre P.; Dohner, K.; Dohner, H.; Dorken, B.; Pezzutto, A. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br. J. Haematol. 2007, 137, 297-306.
34. Takahashi, T.; Tanaka, Y.; Nieda, M.; Azuma, T.; Chiba, S.; Juji, T.; Shibata, Y.; Hirai, H. Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk. Res. 2003, 27, 795-802.
35. Litzow, M. R.; Dietz, A. B.; Bulur, P. A.; Butler, G. W.; Gastineau, D. A.; Hoering, A.; Fink, S. R.; Letendre, L.; Padley, D. J.; Paternoster, S. F.; Tefferi, A.; Vuk-Pavlovic, S. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML. Cytotherapy 2006, 8, 290-298.
36. Simpson, E.; Scott, D.; James, E.; Lombardi, G.; Cwynarski, K.; Dazzi, F.; Millrain, M.; Dyson, P. J. Minor H antigens: genes and peptides. Transpl. Immunol. 2002, 10, 115-123.
37. Marijt, W. A.; Heemskerk, M. H.; Kloosterboer, F. M.; Goulmy, E.; Kester, M. G.; van der Hoorn, M. A.; van Luxemburg-Heys, S. A.; Hoogeboom, M.; Mutis, T.; Drijfhout, J. W.; van Rood, J. J.; Willemze, R.; Falkenburg, J. H. Hematopoiesis-restricted minor histocompatibility antigens HA-1-or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 2742-2747.
38. Kloosterboer, F. M.; van Luxemburg-Heijs, S. A.; van Soest, R. A.; van Egmond, H. M.; Barbui, A. M.; Strijbosch, M. P.; Willemze, R.; Falkenburg, J. H. Minor histocompatibility antigen-specific T cells with multiple distinct specificities can be isolated by direct cloning of IFNgamma-secreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion. Leukemia 2005, 19, 83-90.
39. Warren, E. H.; Fujii, N.; Akatsuka, Y.; Chaney, C. N.; Mito, J. K.; Loeb, K. R.; Gooley, T. A.; Brown, M. L.; Koo, K. K.; Rosinski, K. V.; Ogawa, S.; Matsubara, A.; Appelbaum, F. R.; Riddell, S. R. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 2010, 115, 3869-3878.
40. Li, N.; Matte-Martone, C.; Zheng, H.; Cui, W.; Venkatesan, S.; Tan, H. S.; McNiff, J.; Demetris, A. J.; Roopenian, D.; Kaech, S.; Shlomchik, W. D. Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood 2011, 118, 5965-5976.
41. Rittig, S. M.; Haentschel, M.; Weimer, K. J.; Heine, A.; Muller, M. R.; Brugger, W.; Horger, M. S.; Maksimovic, O.; Stenzl, A.; Hoerr, I.; Rammensee, H. G.; Holderried, T. A.; Kanz, L.; Pascolo, S.; Brossart, P. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol. Ther. 2011, 19, 990-999.
42. Christiansson, L.; Soderlund, S.; Svensson, E.; Mustjoki, S.; Bengtsson, M.; Simonsson, B.; Olsson-Stromberg, U.; Loskog, A. S. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS One. 2013, 8, e55818.
43. Cai, A.; Keskin, D. B.; DeLuca, D. S.; Alonso, A.; Zhang, W.; Zhang, G. L.; Hammond, N. N.; Nardi, V.; Stone, R. M.; Neuberg, D.; Sidney, J.; Brusic, V.; Wu, C. J. Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. Clin. Cancer Res. 2012, 18, 5761-5772.
44. Greiner, J.; Dohner, H.; Schmitt, M. Cancer vaccines for patients with acute myeloid leukemia-definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 2006, 91, 1653-1661.
45. Ohminami, H.; Yasukawa, M.; Fujita, S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000, 95, 286-293.
46. Bornhauser, M.; Thiede, C.; Platzbecker, U.; Kiani, A.; Oelschlaegel, U.; Babatz, J.; Lehmann, D.; Holig, K.; Radke, J.; Tuve, S.; Wermke, M.; Wehner, R.; Jahnisch, H.; Bachmann, M. P.; Rieber, E. P.; Schetelig, J.; Ehninger, G.; Schmitz, M. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T celldepleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. Blood 2011, 117, 7174-7184.
47. Oji, Y.; Oka, Y.; Nishida, S.; Tsuboi, A.; Kawakami, M.; Shirakata, T.; Takahashi, K.; Murao, A.; Nakajima, H.; Narita, M.; Takahashi, M.; Morita, S.; Sakamoto, J.; Tanaka, T.; Kawase, I.; Hosen, N.; Sugiyama, H. WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient. Eur. J. Haematol. 2010, 85, 358-360.
48. Rezvani, K.; Yong, A. S.; Savani, B. N.; Mielke, S.; Keyvanfar, K.; Gostick, E.; Price, D. A.; Douek, D. C.; Barrett, A. J. Graft-versusleukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007, 110, 1924-1932.
49. Kanodia, S.; Wieder, E.; Lu, S.; Talpaz, M.; Alatrash, G.; Clise-Dwyer, K.; Molldrem, J. J. PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS One 2010, 5, e11770.
50. Zeis, M.; Siegel, S.; Wagner, A.; Schmitz, M.; Marget, M.; Kuhl-Burmeister, R.; Adamzik, I.; Kabelitz, D.; Dreger, P.; Schmitz, N.; Heiser, A. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J. Immunol. 2003, 170, 5391-5397.
51. Bocchia, M.; Gentili, S.; Abruzzese, E.; Fanelli, A.; Iuliano, F.; Tabilio, A.; Amabile, M.; Forconi, F.; Gozzetti, A.; Raspadori, D.; Amadori, S.; Lauria, F. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005, 365, 657-662.
52. Chen, J.; Schmitt, A.; Bunjes, D.; Chen, B.; Schmitt, M. The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation. Int. J. Oncol. 2007, 30, 1119-1127.
53. Greiner, J.; Ringhoffer, M.; Taniguchi, M.; Schmitt, A.; Kirchner, D.; Krahn, G.; Heilmann, V.; Gschwend, J.; Bergmann, L.; Dohner, H.; Schmitt, M. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp. Hematol. 2002, 30, 1029-1035.
54. Schmitt, M.; Li, L.; Giannopoulos, K.; Chen, J.; Brunner, C.; Barth, T.; Schmitt, A.; Wiesneth, M.; Dohner, K.; Dohner, H.; Greiner, J. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. Exp. Hematol. 2006, 34, 1709-1719.
55. Mao, H.; Geng, Z.; Liu, W.; Sun, H.; Huang, W. Selection of HLAA2 restricted CML28 peptide by artificial antigen-presenting cells. J. Immunother. 2008, 31, 487-490.
56. Xie, L. H.; Sin, F. W.; Cheng, S. C.; Cheung, Y. K.; Chan, K. T.; Xie, Y.; Xie, Y. Activation of cytotoxic T lymphocytes against CML28-bearing tumors by dendritic cells transduced with a recombinant adeno-associated virus encoding the CML28 gene. Cancer Immunol. Immunother. 2008, 57, 1029-1038.
57. Uziel, O.; Fenig, E.; Nordenberg, J.; Beery, E.; Reshef, H.; Sandbank, J.; Birenbaum, M.; Bakhanashvili, M.; Yerushalmi, R.; Luria, D.; Lahav, M. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomeraseexpressing cell lines. Br. J. Cancer 2005, 92, 1881-1891.
58. Gannage, M.; Abel, M.; Michallet, A. S.; Delluc, S.; Lambert, M.; Giraudier, S.; Kratzer, R.; Niedermann, G.; Saveanu, L.; Guilhot, F.; Camoin, L.; Varet, B.; Buzyn, A.; Caillat-Zucman, S. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J. Immunol. 2005, 174, 8210-8218.
59. Al, Qudaihi G.; Lehe, C.; Dickinson, A.; Eltayeb, K.; Rasheed, W.; Chaudhri, N.; Aljurf, M.; Dermime, S. Identification of a novel peptide derived from the M-phase phosphoprotein 11 (MPP11) leukemic antigen recognized by human CD8+ cytotoxic T lymphocytes. Hematol. Oncol. Stem Cell Ther. 2010, 3, 24-33.
60. Kawano, T.; Ito, M.; Raina, D.; Wu, Z.; Rosenblatt, J.; Avigan, D.; Stone, R.; Kufe, D. MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. Cancer Res. 2007, 67, 11576-11584.
61. Brossart, P.; Heinrich, K. S.; Stuhler, G.; Behnke, L.; Reichardt, V. L.; Stevanovic, S.; Muhm, A.; Rammensee, H. G.; Kanz, L.; Brugger, W. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999, 93, 4309-4317.
62. Brossart, P.; Schneider, A.; Dill, P.; Schammann, T.; Grunebach, F.; Wirths, S.; Kanz, L.; Buhring, H. J.; Brugger, W. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 2001, 61, 6846-6850.
63. Schmidt, S. M.; Schag, K.; Muller, M. R.; Weinschenk, T.; Appel, S.; Schoor, O.; Weck, M. M.; Grunebach, F.; Kanz, L.; Stevanovic, S.; Rammensee, H. G.; Brossart, P. Induction of adipophilinspecific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res. 2004, 64, 1164-1170.